COMBINED MODALITY TREATMENT ACCOUNTS FOR BETTER OUTCOME IN EARLY STAGE LOW RISK HD PATIENTS

Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/11603

DC Field	Value	Language
dc.contributor.author	O. Karanfilski	en_US
dc.contributor.author	M. Lozance	en_US
dc.contributor.author	S. Stankovic	en_US
dc.contributor.author	S. Trajkova	en_US
dc.contributor.author	A. Crcareva	en_US
dc.contributor.author	A. Stojanovic	en_US
dc.date.accessioned	2021-03-31T12:42:13Z	-
dc.date.available	2021-03-31T12:42:13Z	-
dc.date.issued	2003	-
dc.identifier.uri	http://hdl.handle.net/20.500.12188/11603	-
dc.language.iso	en	en_US
dc.relation.ispartof	The Hematology Journal	en_US
dc.subject	Morbus Hodgkin	en_US
dc.subject	low risk	en_US
dc.subject	early stage	en_US
dc.subject	treatment	en_US
dc.title	COMBINED MODALITY TREATMENT ACCOUNTS FOR BETTER OUTCOME IN EARLY STAGE LOW RISK HD PATIENTS	en_US
dc.type	Proceeding article	en_US
dc.relation.conference	The 8-the Annual Congress of the European Hematology Association, Lyon, France, 12-15 June 2003	en_US
item.fulltext	With Fulltext	-
item.grantfulltext	open	-
crisitem.author.dept	Faculty of Medicine	-
crisitem.author.dept	Faculty of Medicine	-
crisitem.author.dept	Faculty of Medicine	-
Appears in Collections:	Faculty of Medicine: Conference papers